Subtitle: Market Intelligence for Extracellular Histone Neutralization, Epigenetic Tool Development, and High-Purity Reagents
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for H4C11 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | H4C11 Recombinant Histone H4 Protein High purity (>95%), Endotoxin <1EU/ug, Sequence Verified, E. coli/HEK293 expression options for unmodified or post-translationally modified forms |
View H4C11 Products |
| Complex | Histone Octamer / Nucleosome Core Particle (NCP) Reconstituted with H4C11, H2A, H2B, H3.1 for chromatin remodeling assays |
View H4C11 Products |
| Gene Delivery | H4C11 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation in histone complementation studies |
View H4C11 Products |
| Benchmark Ab | Anti-H4C11 (Pan-Histone H4) Recombinant rabbit monoclonal for nucleosome detection and neutralization assays |
View H4C11 Products |
| Validator | H4C11 siRNA Set For knockdown and specificity verification in chromatin studies |
View H4C11 Products |
| Related Target: HIST1H3A | Histone H3.1 Synergistic nucleosome component for octamer assembly and cross-reactivity testing |
View HIST1H3A Products |
| Related Target: PAD4 | Peptidylarginine Deiminase 4 Critical enzyme for histone citrullination and NETosis pathway analysis |
View PAD4 Products |
| Related Target: HDAC1 | Histone deacetylase modifying H4C11 Epigenetic enzyme screening and selectivity assays |
View HDAC1 Products |
| Related Target: KAT2A | Histone acetyltransferase acting on H4C11 PTM analysis and HAT inhibitor screening |
View KAT2A Products |
Critical Assay Challenges and TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Nucleosome Assembly & DNA Binding | High-purity H4C11 (>95% by SDS-PAGE, >90% by HPLC) with validated octamer reconstitution efficiency |
| Extracellular Histone Neutralization (Sepsis/NETs) | Endotoxin-controlled (<0.1 EU/µg) preparations suitable for primary cell toxicity assays |
| Post-Translational Modification Specificity | Acetylated/Methylated H4C11 variants (Lys5, Lys8, Lys12, Lys16, Lys20) with mass spec verification |
| Cross-Histone Selectivity | Strict homology screening against H1, H2A, H2B, H3 families to ensure antibody specificity |
| Epigenetic Enzyme Screening (HAT/HDAC) | High-purity (>95%) full-length unmodified histone proteins for precise baseline measurements |
| PTM Analysis (Acetyl/Methyl/Cit) | Sequence Verified proteins ensuring exact lysine/arginine positioning for specific modification assays |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay validation |
| False Positives | Validated siRNA included for specificity checks |
Global Clinical Landscape & Future Outlook
The recognition of extracellular histones as damage-associated molecular patterns (DAMPs) has shifted H4C11 from a structural chromatin component to a therapeutic target for acute inflammatory conditions. While intracellular H4 remains challenging for traditional drug modalities, the extracellular release of histones during NETosis (Neutrophil Extracellular Trap formation) creates opportunities for neutralizing antibody therapies in sepsis, trauma, and autoimmune diseases.
Simultaneously, the race for epigenetic therapeutics involving H4C11 is intensifying, with major players shifting focus from broad inhibitors to highly specific epigenetic modifiers. As first-generation therapies (e.g., HDAC inhibitors) reach the clinic, the next wave of R&D is targeting selective modification pathways and combo-therapies in oncology and rare diseases. Major pharmaceutical players (Novartis, Merck) continue to invest in small-molecule epigenetic modulators, while PROTAC technology is emerging for targeted degradation of epigenetic readers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing mAb | Academic consortia, Biotechs in sepsis | Septic shock, Trauma | Histone-mediated cytotoxicity neutralization assay (Need endotoxin-free H4C11) |
| NET Inhibitors | Pharmaceutical R&D | Autoimmune (SLE, RA) | Citrullinated H4 detection (Need PAD4-modified H4C11 standards) |
| Nucleosome Biomarkers | Diagnostic companies | Lupus monitoring | Anti-nucleosome ELISA (Need intact NCP with H4C11) |
| Cell-Penetrating Peptides | Epigenetic biotechs | Cancer (chromatin disruption) | Competition binding assays (Need fluorescent-labeled H4C11) |
| Small Molecule (HDACi, HATi) | Novartis, Merck | Hematological Malignancies | Selectivity Assay (Need High-Purity Proteins with specific PTM status) |
| PROTACs | Arvinas | Solid Tumors | Degradation Assays (Need Mutant vs WT proteins for specificity) |
| Peptide Therapeutics | Bicycle Therapeutics | Oncology | Binding Affinity (Need Sequence Verified Proteins for SPR/BLI) |
Live H4C11 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: